Molecular Assays Developed for Hantavirus Pulmonary Syndrome
|
By LabMedica International staff writers Posted on 16 Jan 2020 |

Image: This micrograph depicts an atypical, enlarged lymphocyte found in the blood smear from a hantavirus pulmonary syndrome (HPS) patient. This large atypical lymphocyte is an example of one of the laboratory findings, which when combined with a bandemia, i.e., immature white blood cells, and dropping platelet count, is characteristic of HPS (Photo courtesy of Centers for Disease Control and Prevention)
Hantavirus Pulmonary Syndrome (HPS) is a serious and often fatal disease caused by viruses known as hantaviruses. These anthropozoonotic diseases comprising of two clinical entities: Hemorrhagic Fever with Renal Syndrome (HFRS), which occurs in the Old World, and Hantavirus Pulmonary Syndrome (HPS) in the New World.
Laboratory diagnosis of HPS is often conducted by enzyme-linked immunosorbent assay (ELISA) for detection of immunoglobulin G (IgG) and IgM specific antibodies in serum or blood of suspected patients. Given that IgM antibodies are detectable early in the disease, IgM ELISA is considered the reference method for HPS diagnostics.
Scientists at the Evandro Chagas Institute (Ananindeua, Brazil) have developed real-time polymerase chain reaction (RT-qPCR) and semi-nested RT-qPCR assays for the diagnosis of HPS. The assays were developed for detection and quantification of four hantaviruses strains circulating in the Brazilian Amazon. assays were used to test two groups of samples: one comprising of 50 patients with disease and other containing samples from 50 healthy individuals according to IgM-ELISA results. A third group of 27 samples infected with other pathogens were tested for specificity analysis.
A consensus region in the N gene of these hantaviruses was used to design the primer sets and a hydrolysis probe. In vitro transcribed RNA was diluted in standards with known concentration. MS2 bacteriophage RNA was detected together with hantavirus RNA as an exogenous control in a duplex reaction. RT-qPCR efficiency was around 100% and the limit of detection was 0.9 copies/μL of RNA for RT-qPCR and 10 copies/μL of RNA for Semi-nested RT-PCR. There was no amplification of either negative samples or samples positive to other pathogens. Sample reactions were performed in triplicate in ViiA7 qPCR System (Applied Biosystems, Thermo-Fisher Scientific, Waltham, MA, USA).
The investigators reported that the RT-qPCR was more sensitive than semi-nested RT-PCR, being able to detect three samples undetected by conventional RT-PCR. RT-qPCR clinical sensitivity, specificity and general accuracy values were 92.5%, 100% and 97.63%, respectively. Taken together, these results indicate that both RT-qPCR and Semi-nested RT-PCR assays are efficient, sensitive and specific tools for genome detection of hantaviruses circulating in the Amazon region. In addition to being more sensitive, RT-qPCR offers other advantages such as agility in generating results, about three times faster than conventional assays and automation capability which leads to lower risk of contamination and greater reproducibility. The study was published on December 26, 2019 in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Evandro Chagas Institute
Applied Biosystems
Laboratory diagnosis of HPS is often conducted by enzyme-linked immunosorbent assay (ELISA) for detection of immunoglobulin G (IgG) and IgM specific antibodies in serum or blood of suspected patients. Given that IgM antibodies are detectable early in the disease, IgM ELISA is considered the reference method for HPS diagnostics.
Scientists at the Evandro Chagas Institute (Ananindeua, Brazil) have developed real-time polymerase chain reaction (RT-qPCR) and semi-nested RT-qPCR assays for the diagnosis of HPS. The assays were developed for detection and quantification of four hantaviruses strains circulating in the Brazilian Amazon. assays were used to test two groups of samples: one comprising of 50 patients with disease and other containing samples from 50 healthy individuals according to IgM-ELISA results. A third group of 27 samples infected with other pathogens were tested for specificity analysis.
A consensus region in the N gene of these hantaviruses was used to design the primer sets and a hydrolysis probe. In vitro transcribed RNA was diluted in standards with known concentration. MS2 bacteriophage RNA was detected together with hantavirus RNA as an exogenous control in a duplex reaction. RT-qPCR efficiency was around 100% and the limit of detection was 0.9 copies/μL of RNA for RT-qPCR and 10 copies/μL of RNA for Semi-nested RT-PCR. There was no amplification of either negative samples or samples positive to other pathogens. Sample reactions were performed in triplicate in ViiA7 qPCR System (Applied Biosystems, Thermo-Fisher Scientific, Waltham, MA, USA).
The investigators reported that the RT-qPCR was more sensitive than semi-nested RT-PCR, being able to detect three samples undetected by conventional RT-PCR. RT-qPCR clinical sensitivity, specificity and general accuracy values were 92.5%, 100% and 97.63%, respectively. Taken together, these results indicate that both RT-qPCR and Semi-nested RT-PCR assays are efficient, sensitive and specific tools for genome detection of hantaviruses circulating in the Amazon region. In addition to being more sensitive, RT-qPCR offers other advantages such as agility in generating results, about three times faster than conventional assays and automation capability which leads to lower risk of contamination and greater reproducibility. The study was published on December 26, 2019 in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Evandro Chagas Institute
Applied Biosystems
Latest Microbiology News
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








